Grace Therapeutics/$GRCE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Grace Therapeutics
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
Ticker
$GRCE
Sector
Primary listing
Employees
6
Headquarters
Website
GRCE Metrics
BasicAdvanced
$34m
-
-$0.38
0.75
-
Price and volume
Market cap
$34m
Beta
0.75
52-week high
$5.18
52-week low
$1.79
Average daily volume
329k
Financial strength
Current ratio
14.962
Quick ratio
14.558
Profitability
EBITDA (TTM)
-11.241
Effective tax rate (TTM)
14.55%
Management effectiveness
Return on assets (TTM)
-10.84%
Return on equity (TTM)
-10.22%
Valuation
Price to book
0.53
Price to tangible book (TTM)
2.2
Price to free cash flow (TTM)
-3.431
Free cash flow yield (TTM)
-29.14%
Free cash flow per share (TTM)
-0.647
Growth
Earnings per share change (TTM)
-67.14%
3-year earnings per share growth (CAGR)
-42.73%
GRCE News
AllArticlesVideos
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Business Wire·3 weeks ago
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug
Benzinga·2 months ago
US FDA declines to approve Grace Therapeutics' drug for a type of stroke
Reuters·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs